Logo image
Cost-Effectiveness of a Community-Integrated Home-Based Depression Intervention in Older African Americans
Journal article   Open access   Peer reviewed

Cost-Effectiveness of a Community-Integrated Home-Based Depression Intervention in Older African Americans

Laura T. Pizzi, Eric Jutkowitz, Kevin D. Frick, Dong-Churl Suh, Katherine M. Prioli and Laura N. Gitlin
Journal of the American Geriatrics Society (JAGS), v 62(12), pp 2288-2295
01 Dec 2014
PMID: 25516025
url
https://europepmc.org/articles/pmc4270093View
Accepted (AM)Open Access (License Unspecified) Open

Abstract

Geriatrics & Gerontology Gerontology Life Sciences & Biomedicine Science & Technology
ObjectivesTo test the cost-effectiveness of a home-based depression program: Beat the Blues (BTB). DesignA cost-effectiveness analysis as part of a previously reported randomized controlled trial that compared BTB with a wait-list control group. SettingCommunity. ParticipantsEnglish-speaking, cognitively intact (Mini-Mental State Examination score 24), African Americans aged 55 and older with depressive symptoms (Patient Health Questionnaire score 5) (N=129). InterventionParticipants randomly assigned to BTB received up to 10 home visits over 4months from licensed social workers who provided care management, referral and linkage, stress reduction, depression education, and behavioral activation to help participants achieve self-identified goals. MeasurementsIncremental cost-effectiveness ratios (ICERs) of BTB versus wait-list controls during the 4-month study period. The primary ICER was defined as cost per quality-adjusted life year (QALY) using the Euro Quality of Life 5D (EQ-5D) and secondarily using the Health Utilities Index-3 (HUI-3). Additional ICERs were calculated using clinical measures (cost per depression improvement, cost per depression remission). Costs included BTB intervention, depression-related healthcare visits and medications, caregiver time, and social services. ResultsBTB cost per participant per month was $146. Base case ICERs were $64,896 per QALY (EQ-5D) and $36,875 per QALY (HUI-3). Incremental cost was $2,906 per depression improvement and $3,507 per remission. Univariate and probabilistic sensitivity analyses yielded a cost/QALY range of $20,500 to $76,500. ConclusionBased on the range of cost-effectiveness values resulting from this study, BTB is a cost-effective treatment for managing depressive symptoms in older African Americans that compares favorably with the cost-effectiveness of previously tested approaches.

Metrics

9 Record Views
14 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Geriatrics & Gerontology
Gerontology
Logo image